Tscan Therapeutics Inc (NASDAQ: TCRX) on Monday, plunged -36.08% from the previous trading day, before settling in for the closing price of $1.94. Within the past 52 weeks, TCRX’s price has moved between $1.02 and $6.22.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -14.41%. The company achieved an average annual earnings per share of -10.38%. With a float of $46.42 million, this company’s outstanding shares have now reached $52.47 million.
Tscan Therapeutics Inc (TCRX) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Tscan Therapeutics Inc is 18.20%, while institutional ownership is 59.62%. The most recent insider transaction that took place on May 19 ’25, was worth 1,666,553. In this transaction 10% Owner of this company bought 1,388,794 shares at a rate of $1.20, taking the stock ownership to the 6,746,141 shares. Before that another transaction happened on May 20 ’25, when Company’s 10% Owner bought 1,200,000 for $1.20, making the entire transaction worth $1,440,000. This insider now owns 7,946,141 shares in total.
Tscan Therapeutics Inc (TCRX) Performance Highlights and Predictions
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.25 earnings per share (EPS) for the period topping the consensus outlook (set at -0.29) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.32 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -10.38% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.06% during the next five years compared to -14.41% drop over the previous five years of trading.
Tscan Therapeutics Inc (NASDAQ: TCRX) Trading Performance Indicators
Tscan Therapeutics Inc (TCRX) is currently performing well based on its current performance indicators. A quick ratio of 7.06 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.11.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.10, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -1.18 in one year’s time.
Technical Analysis of Tscan Therapeutics Inc (TCRX)
The latest stats from [Tscan Therapeutics Inc, TCRX] show that its last 5-days average volume of 1.61 million was superior to 0.49 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 16.83%.
During the past 100 days, Tscan Therapeutics Inc’s (TCRX) raw stochastic average was set at 9.52%, which indicates a significant increase from 9.52% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.2083 in the past 14 days, which was higher than the 0.1421 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.9666, while its 200-day Moving Average is $1.7790. Now, the first resistance to watch is $1.4467. This is followed by the second major resistance level at $1.6533. The third major resistance level sits at $1.8267. If the price goes on to break the first support level at $1.0667, it is likely to go to the next support level at $0.8933. Assuming the price breaks the second support level, the third support level stands at $0.6867.
Tscan Therapeutics Inc (NASDAQ: TCRX) Key Stats
Market capitalization of the company is 70.37 million based on 56,748K outstanding shares. Right now, sales total 2,820 K and income totals -127,500 K. The company made 3,080 K in profit during its latest quarter, and -36,950 K in sales during its previous quarter.
